Analyzing eye fluid biomarkers in patients with retinal diseases
Analysis of Biomarkers From Patients With Chorioretinal Diseases
This study is trying to see if certain eye fluids can help us understand how serious retinal diseases like diabetic retinopathy and age-related macular degeneration are in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | Kyungpook National University Hospital Academic / other |
| Locations | 1 site (Daegu, Kyungsangpookdo) |
| Trial ID | NCT02026843 on ClinicalTrials.gov |
What this trial studies
This observational study investigates ocular biomarkers in patients suffering from chorioretinal diseases such as diabetic retinopathy and age-related macular degeneration. It includes a total of 100 participants, with 50 patients diagnosed with chorioretinal diseases and 50 control patients undergoing cataract surgery or vitrectomy. Ocular fluids and blood samples are collected prior to treatment to analyze the levels of specific biomarkers. The goal is to better understand the relationship between these biomarkers and the severity of retinal diseases.
Who should consider this trial
Good fit: Ideal candidates are adults over 20 years with chorioretinal diseases or those requiring cataract surgery.
Not a fit: Patients under 20 years or those with recent ocular trauma or infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and therapeutic strategies for patients with chorioretinal diseases.
How similar studies have performed: Other studies have shown promise in analyzing ocular biomarkers for retinal diseases, suggesting this approach has potential.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age over 20 years * patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity. * patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. * control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders. Exclusion Criteria: * under the age of 20 years * patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor * patients that did not signed the informed consent of the trial * patients with intraocular inflammations or infections that requiring any pharmaceutical agent * patients with recent ocular trauma
Where this trial is running
Daegu, Kyungsangpookdo
- Dong Ho Park — Daegu, Kyungsangpookdo, South Korea (Recruiting)
Study contacts
- Principal investigator: Dong Ho Park, M.D — Kyungpook National University Hospital
- Study coordinator: Dong Ho Park, M.D.
- Email: sarasate2222@gmail.com
- Phone: 82-53-420-5813
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.